Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | AURKA | O14965 | 5/20 | 0.50 |
| ▸ | TEK | Q02763 | 5/20 | 0.50 |
| ▸ | MET | P08581 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380952 | 0.91 | DGAT2 (0.58) | DGAT2KDRAURKATEKMET | |
| SCHEMBL2379174 | 0.84 | DGAT2 (0.55) | DGAT2KDRPIM1PIM2CHEK1 | |
| SCHEMBL14571338 | 0.80 | DGAT2 (0.46) | DGAT2KDRTEKFLT1CHEK1 | |
| SCHEMBL2380276 | 0.79 | KDR (0.58) | DGAT2KDRTEKALDH1A1FLT1 | |
| SCHEMBL2380673 | 0.79 | MCL1 (0.49) | DGAT2KDRCHEK1 | |
| SCHEMBL2381295 | 0.78 | KDM4E (0.46) | DGAT2KDRALDH1A1CHEK1 | |
| SCHEMBL2380917 | 0.78 | SERPINE1 (0.47) | DGAT2KDRCHEK1BRAF | |
| SCHEMBL2380392 | 0.76 | KDR (0.60) | KDRAURKATEKMETALDH1A1 | |
| SCHEMBL2380290 | 0.76 | KDR (0.49) | KDRFLT1 | |
| SCHEMBL2381046 | 0.76 | KDR (0.49) | DGAT2KDRSMN1; SMN2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | DGAT2 3636/4885KDR 260/4885AURKA 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.